Method of treating food allergies by administering a nanoparticle comprising heparin and chitosan encapsulating IL-12

Patent metadata

Field	Value
Publication number	US-9782475-B2
Application number	US-201414336411-A
Country	US
Kind code	B2
Filing date	Jul 21, 2014
Priority date	Oct 4, 2010
Publication date	Oct 10, 2017
Grant date	Oct 10, 2017

Abstract

Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1α, IL-10, IL-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin with a second composition comprising chitosan in the presence of at least one cytokine to form a third composition. Further provided are methods of modulating an immune response comprising co-administering to a subject an antigen or vaccine with nanoparticles comprising heparin, chitosan, and at least one cytokine.

First claim

We claim:

1. A method of treating food allergies comprising administering to a subject a nanoparticle comprising:
heparin; and
chitosan,
wherein the heparin and the chitosan nanoparticle encapsulates IL-12, and

wherein the nanoparticle is administered by a route selected from oral, sublingual, intramuscular, subcutaneous, intravenous, transdermal, topical, parenteral, buccal, rectal, mucosal, intranasal, injection, inhalation, implant, and a combination thereof.

2. The method of claim 1 , wherein the nanoparticle further comprises an antigen, wherein the antigen comprises at least one of a protein, peptide, polysaccharide, lipid, glycoprotein, glycolipid, glycoprotein, lipoprotein, lipopolysaccharide, or a combination thereof.

3. The method of claim 1 , wherein the nanoparticle further comprises at least one immunomodulatory agent selected from the group consisting of TNF, IL-1α, IL-2, IL-23, IL-18, IL-10, and IFN.

4. The method of claim 2 , wherein the antigen is the substance that provoked the food allergy.

5. The method of claim 1 , wherein IgG2a levels are increased in the subject after administration of the nanoparticle.

Assignees

• Univ Duke

Inventors

• Abraham Soman
• Leong Kam
• Staats Herman
• St John Ashley

Classifications

• A61K2039/55505

  Inorganic adjuvants · CPC title

• A61K2039/55527

  Interleukins · CPC title

• A61K38/21

  Interferons {[IFN]} · CPC title

• A61K38/2006

  IL-1 · CPC title

• Y10S977/773

  Nanoparticle, i.e. structure having three dimensions of 100 nm or less · CPC title